These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 19057413

  • 21. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [Abstract] [Full Text] [Related]

  • 22. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [Abstract] [Full Text] [Related]

  • 23. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
    Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D.
    J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
    [Abstract] [Full Text] [Related]

  • 24. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [Abstract] [Full Text] [Related]

  • 25. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B.
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [Abstract] [Full Text] [Related]

  • 27. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL.
    Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
    [Abstract] [Full Text] [Related]

  • 28. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
    Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N, HBBI Study Group.
    J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
    [Abstract] [Full Text] [Related]

  • 29. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
    Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM.
    Biol Psychiatry; 2008 Mar 01; 63(5):524-9. PubMed ID: 17651705
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
    Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mästele A, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2008 Feb 01; 18(1):54-69. PubMed ID: 18294089
    [Abstract] [Full Text] [Related]

  • 31. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A.
    Can J Psychiatry; 2003 Dec 01; 48(11):716-21. PubMed ID: 14733451
    [Abstract] [Full Text] [Related]

  • 32. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ.
    Am J Psychiatry; 2005 Aug 01; 162(8):1535-8. PubMed ID: 16055779
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 01; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 34. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M.
    Psychopharmacol Bull; 2010 Jan 01; 43(2):45-66. PubMed ID: 21052042
    [Abstract] [Full Text] [Related]

  • 35. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
    Mozes T, Ebert T, Michal SE, Spivak B, Weizman A.
    J Child Adolesc Psychopharmacol; 2006 Aug 01; 16(4):393-403. PubMed ID: 16958565
    [Abstract] [Full Text] [Related]

  • 36. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T, Assunção-Talbott S, Whitehead R, Pikalov A.
    J Child Adolesc Psychopharmacol; 2010 Feb 01; 20(1):33-8. PubMed ID: 20166794
    [Abstract] [Full Text] [Related]

  • 37. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ.
    BMC Psychiatry; 2005 Jan 13; 5():3. PubMed ID: 15649317
    [Abstract] [Full Text] [Related]

  • 38. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S.
    Am J Psychiatry; 1998 Jul 13; 155(7):914-20. PubMed ID: 9659857
    [Abstract] [Full Text] [Related]

  • 39. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A.
    Am J Psychiatry; 2006 May 13; 163(5):790-9. PubMed ID: 16648318
    [Abstract] [Full Text] [Related]

  • 40. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M, de Jesus Mari J, Breier A, Maria Costa A, Pondé de Sena E, Hotopf M.
    J Clin Psychiatry; 2005 Jul 13; 66(7):831-8. PubMed ID: 16013897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.